An Emerging Consensus
By Richard Hayes,
Science Progress
| 11. 06. 2008
Human Biotechnology Policies Around the World
The new human biotechnologies have the potential for both great good and great harm. If used responsibly they could lead to medical advances and improved health outcomes. If misapplied they could exacerbate health disparities and generate new forms of discrimination and inequality. If we are to realize their benefits yet avoid their risks we will need regulations, laws, and guidelines at both national and international levels.
But how and where should the lines be drawn? If drawn too tightly they could constrain valuable medical research. If drawn too loosely they could open the door to a Gattaca-like world of neo-eugenic practices and ideologies.
In the United States serious discussion of these questions has been thwarted for the past eight years by partisanship and polarization, and constructive engagement by the Bush administration at the international level has been effectively nil.
The good news, however, is that during this same period many countries have been developing comprehensive human biotech policies that strike a practicable and socially responsible balance between being overly restrictive and overly permissive. A survey of all 192 countries...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...